NUVB-WT

Investor Moves

Name	Value	Action	Change	Price	Last Price
Ken GriffinCitadel Advisors $-24.3K ExitQ1 2026 $24k -- $0.0671
Ken GriffinCitadel Advisors $9.5K AddQ4 2025 $9.5k -- $0.0671
Ken GriffinCitadel Advisors $-5.0K TrimQ3 2025 $5k -- $0.0671
Ken GriffinCitadel Advisors $-3.7K TrimQ2 2025 $3.7k -- $0.0671
Ken GriffinCitadel Advisors $6.5K AddQ1 2025 $6.5k -- $0.0671
Ken GriffinCitadel Advisors $9.6K AddQ4 2024 $9.6k -- $0.0671

Insider Trades

Name	Value	Action	Price	Last Price
Liu DongfangCHIEF MEDICAL OFFICER $251k50k shares SellApr 17, 2026 $5.02 $0.0671
Wentworth KerryCHIEF REGULATORY OFFICER $184k36.8k shares SellApr 17, 2026 $5.01 $0.0671
Wentworth KerryCHIEF REGULATORY OFFICER $904k200k shares SellApr 6, 2026 $4.52 $0.0671
Liu DongfangCHIEF MEDICAL OFFICER $1M150k shares SellDec 1, 2025 $7.82 $0.0671
Liu DongfangCHIEF MEDICAL OFFICER $80k10k shares SellNov 26, 2025 $8.00 $0.0671
Liu DongfangCHIEF MEDICAL OFFICER $75k10k shares SellNov 25, 2025 $7.50 $0.0671

Trade NUVB-WT

About Nuvation Bio Inc.

Nuvation Bio, Inc. operates as a biopharmaceutical firm dedicated to addressing critical unmet needs within oncology. It does so by pioneering distinctive and innovative therapeutic candidates. Its exclusive pipeline features six cutting-edge cancer treatment products, each employing a unique mechanism of action and specifically designed to combat some of the most challenging types of malignancies. David Hung established the company on March 20, 2018, and its headquarters are situated in New York, NY.

CEO: David T. Hung
IPO Date: Aug 26, 2020

Market Data

Open: $0.0641
High: $0.0641
Low: $0.0616
Volume: 6.8M
Avg Volume: 52K
52W High: $0.1444
52W Low: $0.0051

Valuation

Market Cap: $21.5M
Enterprise Value: $1.8B
Dividend Yield: 0.00%

Financials

Free Cash Flow: -$173.8M
Revenue: $62.9M
Net Income: -$204.6M
Cash: $164.1M
Debt: $10.1M

Events

EarningsMay 4

EPS est. -0.04317 · actual 0.02